Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Apomorphine: North American clinical experience.

Mark Stacy1

  • 1Movement Disorders Program, Duke University, Durham, North Carolina 27705, USA.

Neurology
|March 24, 2004
PubMed
Summary

Subcutaneous apomorphine injections offer significant Parkinson's disease (PD) symptom relief, comparable to levodopa. Early PD patients experience longer benefits than advanced cases, with rapid onset and manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.

Movement disorders : official journal of the Movement Disorder Society·2019
Same author

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

CNS spectrums·2019
Same author

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

CNS spectrums·2018
Same author

The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?

Parkinsonism & related disorders·2018
Same author

Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2α Signaling as a Generalizable Mechanism for Dystonia.

Neuron·2016
Same author

Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry.

Movement disorders clinical practice·2016

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease (PD) is a progressive neurodegenerative disorder.
  • Current treatments like levodopa can have limitations over time.

Purpose of the Study:

  • To review North American clinical trials of subcutaneous apomorphine in Parkinson's disease patients.
  • To analyze cumulative safety data for apomorphine in the US.

Main Methods:

  • Review of North American clinical trials and US safety data for subcutaneous apomorphine.
  • Analysis of dosing, efficacy, and adverse events from pivotal and NIH studies.

Main Results:

  • Subcutaneous apomorphine demonstrated statistically significant benefits compared to placebo, mirroring levodopa response.
  • Advanced PD patients showed reduced response duration and increased onset time versus levodopa-naïve subjects.
  • Apomorphine showed rapid onset (7.5 min) and up to 90 min duration of benefit.
  • Common serious adverse events included dyskinesias (21%), hallucinations (11%), and orthostatic hypotension (9%).

Conclusions:

  • Subcutaneous apomorphine is an effective treatment for Parkinson's disease, with potential for greater potency than other agonists.
  • Dosing and response characteristics vary with disease progression.
  • Apomorphine offers rapid symptomatic relief but requires careful monitoring for adverse events.

Related Experiment Videos